RxDoctor Payments Data

Megan Quella

Family · Springfield, MONPI 1194356535

Payments from drug & device makers

$1,445in general payments, 2019–2025

Across 66 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$255
  • AstraZeneca$202
  • Amgen$202
  • Lilly USA, LLC$105
  • Dexcom, Inc.$105
  • Otsuka America Pharmaceutical, Inc.$70
  • plus $505 from 20 others

What the payments were for

  • Food & beverage$1,445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,445 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide29$36,360
JardianceEmpagliflozin43$34,603
Tresiba Flextouch U-200Insulin Degludec12$18,494
TrulicityDulaglutide14$15,571
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$15,140
FarxigaDapagliflozin Propanediol18$11,443
Soliqua 100-33Insulin Glargine/Lixisenatide11$11,300
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,607
Humalog Kwikpen U-100Insulin Lispro23$7,425
Novolog FlexpenInsulin Aspart25$5,132
Insulin Lispro Kwikpen U-100Insulin Lispro16$3,041
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,899
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$1,947
Tizanidine Hcl29$1,428
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic14$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$255$36,36029 claims
Boehringer IngelheimJardiance$51$34,60343 claims
AstraZenecaFarxiga, Breztri Aerosphere$202$21,05129 claims
Lilly USA, LLCTrulicity$105$15,57114 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$46$11,30011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.

Other family in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →